pMMR
About
Biomarker Type: Mismatch Repair
Present: True
Status: Proficient
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | pMMR | Endometrial Carcinoma | Pembrolizumab | |
| EMA (1) | pMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Olaparib, Paclitaxel | |
| EMA (1) | pMMR | Endometrial Carcinoma | Durvalumab, Olaparib |